Do analysts prefer JSPR or RLYB?

Jasper Therapeutics currently has a consensus price target of $8.17, indicating a potential upside of 1,093.96%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer JSPR or RLYB?

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 1 articles in the media. Rallybio's average media sentiment score of 1.51 beat Jasper Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, JSPR or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is JSPR or ACRV more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Acrivon Therapeutics N/A -70.14% -61.60%

Does the media prefer JSPR or ACRV?

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for Acrivon Therapeutics and 1 mentions for Jasper Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.63 beat Jasper Therapeutics' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, JSPR or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is JSPR or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% OKYO Pharma N/A N/A N/A

Does the media refer more to JSPR or OKYO?

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 1 articles in the media. OKYO Pharma's average media sentiment score of 1.89 beat Jasper Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, JSPR or ACET?

Adicet Bio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is JSPR or ACET more profitable?

Adicet Bio's return on equity of -74.90% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Adicet Bio N/A -74.90% -60.87%

Does the media refer more to JSPR or ACET?

In the previous week, Adicet Bio had 5 more articles in the media than Jasper Therapeutics. MarketBeat recorded 6 mentions for Adicet Bio and 1 mentions for Jasper Therapeutics. Adicet Bio's average media sentiment score of 0.57 beat Jasper Therapeutics' score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adicet Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Jasper Therapeutics (JSPR) Competitors

$0.68 0.00 (-0.35%)

As of 09:48 AM Eastern

Compare

JSPR vs. ATRA, RLYB, ACRV, OKYO, and ACET

Should you buy Jasper Therapeutics stock or one of its competitors? Jasper Therapeutics's main competitors and comparable companies include Atara Biotherapeutics (ATRA), Rallybio (RLYB), Acrivon Therapeutics (ACRV), OKYO Pharma (OKYO), and Adicet Bio (ACET). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jasper Therapeutics compare to Atara Biotherapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Jasper Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

Jasper Therapeutics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

In the previous week, Jasper Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 1 mentions for Jasper Therapeutics and 0 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Jasper Therapeutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Atara Biotherapeutics	Positive

Atara Biotherapeutics has higher revenue and earnings than Jasper Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A

Jasper Therapeutics currently has a consensus price target of $8.17, suggesting a potential upside of 1,093.96%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential downside of 0.31%. Given Jasper Therapeutics' higher probable upside, research analysts plainly believe Jasper Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Atara Biotherapeutics beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Jasper Therapeutics compare to Rallybio?

Jasper Therapeutics (NASDAQ:JSPR) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Jasper Therapeutics has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.85, meaning that its stock price is 185% less volatile than the broader market.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jasper Therapeutics currently has a consensus price target of $8.17, indicating a potential upside of 1,093.96%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Jasper Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Rallybio	-911.07%	-40.53%	-38.13%

Rallybio has higher revenue and earnings than Jasper Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Rallybio	$860K	104.65	-$8.98M	-$4.34	N/A

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 1 articles in the media. Rallybio's average media sentiment score of 1.51 beat Jasper Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Jasper Therapeutics and Rallybio tied by winning 7 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Acrivon Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Acrivon Therapeutics' return on equity of -70.14% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Jasper Therapeutics presently has a consensus price target of $8.17, indicating a potential upside of 1,093.96%. Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 552.17%. Given Jasper Therapeutics' higher possible upside, research analysts plainly believe Jasper Therapeutics is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for Acrivon Therapeutics and 1 mentions for Jasper Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.63 beat Jasper Therapeutics' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jasper Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Summary

Jasper Therapeutics beats Acrivon Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to OKYO Pharma?

Jasper Therapeutics (NASDAQ:JSPR) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

OKYO Pharma's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
OKYO Pharma	N/A	N/A	N/A

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 1 articles in the media. OKYO Pharma's average media sentiment score of 1.89 beat Jasper Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OKYO Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Jasper Therapeutics has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

Jasper Therapeutics presently has a consensus target price of $8.17, suggesting a potential upside of 1,093.96%. OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 260.25%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Jasper Therapeutics and OKYO Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Jasper Therapeutics compare to Adicet Bio?

Jasper Therapeutics (NASDAQ:JSPR) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Adicet Bio had 5 more articles in the media than Jasper Therapeutics. MarketBeat recorded 6 mentions for Adicet Bio and 1 mentions for Jasper Therapeutics. Adicet Bio's average media sentiment score of 0.57 beat Jasper Therapeutics' score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adicet Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 3.4% of Adicet Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jasper Therapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Jasper Therapeutics presently has a consensus price target of $8.17, suggesting a potential upside of 1,093.96%. Adicet Bio has a consensus price target of $46.80, suggesting a potential upside of 392.68%. Given Jasper Therapeutics' higher possible upside, equities analysts plainly believe Jasper Therapeutics is more favorable than Adicet Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Adicet Bio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

Adicet Bio's return on equity of -74.90% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Adicet Bio	N/A	-74.90%	-60.87%

Summary

Adicet Bio beats Jasper Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.76M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.56%
P/E Ratio	-0.43	12.66	273.31	25.25
Price / Sales	N/A	1,336.32	622.12	98.12
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	17.10	16.81	13.08	6.14
Net Income	-$75.80M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.24%	0.14%	0.52%	-0.31%
1 Month Performance	2.09%	8.28%	5.63%	0.64%
1 Year Performance	-74.57%	52.61%	25.31%	14.83%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	1.6333 of 5 stars	$0.68 -0.3%	$8.17 +1,094.0%	-74.8%	$22.76M	N/A	N/A	20
ATRA Atara Biotherapeutics	1.4974 of 5 stars	$8.90 -3.3%	$9.50 +6.7%	-24.5%	$92.35M	$120.77M	N/A	330
RLYB Rallybio	1.5956 of 5 stars	$16.79 -0.1%	N/A	+265.4%	$89.27M	$860K	N/A	40	Positive News
ACRV Acrivon Therapeutics	3.1763 of 5 stars	$2.09 +1.5%	$13.50 +545.9%	+53.7%	$88.28M	N/A	N/A	58	Analyst Upgrade
OKYO OKYO Pharma	3.1582 of 5 stars	$1.52 -9.0%	$5.67 +272.8%	-31.7%	$87.64M	N/A	N/A	7	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ATRA, RLYB, ACRV, OKYO, and ACET

How does Jasper Therapeutics compare to Atara Biotherapeutics?

Summary

How does Jasper Therapeutics compare to Rallybio?

Summary

How does Jasper Therapeutics compare to Acrivon Therapeutics?

Summary

How does Jasper Therapeutics compare to OKYO Pharma?

Summary

How does Jasper Therapeutics compare to Adicet Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ATRA, RLYB, ACRV, OKYO, and ACET

How does Jasper Therapeutics compare to Atara Biotherapeutics?

Is JSPR or ATRA more profitable?

Which has more risk & volatility, JSPR or ATRA?

Does the media favor JSPR or ATRA?

Which has better earnings and valuation, JSPR or ATRA?

Do analysts rate JSPR or ATRA?

Do insiders & institutionals have more ownership in JSPR or ATRA?

Summary

How does Jasper Therapeutics compare to Rallybio?

Which has more volatility & risk, JSPR or RLYB?

Do institutionals & insiders believe in JSPR or RLYB?

Do analysts prefer JSPR or RLYB?

Is JSPR or RLYB more profitable?

Which has stronger valuation and earnings, JSPR or RLYB?

Does the media prefer JSPR or RLYB?

Summary

How does Jasper Therapeutics compare to Acrivon Therapeutics?

Do institutionals and insiders believe in JSPR or ACRV?

Is JSPR or ACRV more profitable?

Do analysts prefer JSPR or ACRV?

Does the media prefer JSPR or ACRV?

Which has more risk & volatility, JSPR or ACRV?

Which has preferable earnings and valuation, JSPR or ACRV?

Summary

How does Jasper Therapeutics compare to OKYO Pharma?

Which has higher earnings and valuation, JSPR or OKYO?

Do insiders & institutionals hold more shares of JSPR or OKYO?

Is JSPR or OKYO more profitable?

Does the media refer more to JSPR or OKYO?

Which has more risk and volatility, JSPR or OKYO?

Do analysts prefer JSPR or OKYO?

Summary

How does Jasper Therapeutics compare to Adicet Bio?

Does the media refer more to JSPR or ACET?

Do institutionals and insiders hold more shares of JSPR or ACET?

Which has more risk & volatility, JSPR or ACET?

Do analysts recommend JSPR or ACET?

Which has better valuation and earnings, JSPR or ACET?

Is JSPR or ACET more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools